BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 38396769)

  • 1. Inhibitors of NAD
    Ghanem MS; Caffa I; Monacelli F; Nencioni A
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in NAD-Lowering Agents for Cancer Treatment.
    Ghanem MS; Monacelli F; Nencioni A
    Nutrients; 2021 May; 13(5):. PubMed ID: 34068917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Versatile Continuous Fluorometric Enzymatic Assay for Targeting Nicotinate Phosphoribosyltransferase.
    Minazzato G; Marangoni E; Fortunato C; Petrelli R; Cappellacci L; Del Bello F; Sorci L; Gasparrini M; Piacente F; Bruzzone S; Raffaelli N
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
    Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
    Chen H; Wang S; Zhang H; Nice EC; Huang C
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
    Ghanem MS; Caffa I; Del Rio A; Franco J; Parenti MD; Monacelli F; Cea M; Khalifa A; Nahimana A; Duchosal MA; Ravera S; Bertola N; Bruzzone S; Nencioni A; Piacente F
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discovery targeting nicotinamide phosphoribosyltransferase (NAMPT): Updated progress and perspectives.
    Wen F; Gui G; Wang X; Ye L; Qin A; Zhou C; Zha X
    Bioorg Med Chem; 2024 Feb; 99():117595. PubMed ID: 38244254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK
    Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the Nicotinamide Salvage Pathway as a New Toxification Route for Antimetabolites.
    Buonvicino D; Mazzola F; Zamporlini F; Resta F; Ranieri G; Camaioni E; Muzzi M; Zecchi R; Pieraccini G; Dölle C; Calamante M; Bartolucci G; Ziegler M; Stecca B; Raffaelli N; Chiarugi A
    Cell Chem Biol; 2018 Apr; 25(4):471-482.e7. PubMed ID: 29478906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening.
    Takeuchi M; Niimi T; Masumoto M; Orita M; Yokota H; Yamamoto T
    Biol Pharm Bull; 2014; 37(1):31-6. PubMed ID: 24389478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience.
    Montecucco F; Cea M; Bauer I; Soncini D; Caffa I; Lasigliè D; Nahimana A; Uccelli A; Bruzzone S; Nencioni A
    Curr Drug Targets; 2013 Jun; 14(6):637-43. PubMed ID: 23531116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
    Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
    Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
    Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
    J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.
    Duarte-Pereira S; Pereira-Castro I; Silva SS; Correia MG; Neto C; da Costa LT; Amorim A; Silva RM
    Oncotarget; 2016 Jan; 7(2):1973-83. PubMed ID: 26675378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
    Hasmann M; Schemainda I
    Cancer Res; 2003 Nov; 63(21):7436-42. PubMed ID: 14612543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway.
    Shats I; Williams JG; Liu J; Makarov MV; Wu X; Lih FB; Deterding LJ; Lim C; Xu X; Randall TA; Lee E; Li W; Fan W; Li JL; Sokolsky M; Kabanov AV; Li L; Migaud ME; Locasale JW; Li X
    Cell Metab; 2020 Mar; 31(3):564-579.e7. PubMed ID: 32130883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of Allosteric Modulation of Nicotinamide Phosphoribosyltransferase to Elevate Cellular NAD
    Ratia KM; Shen Z; Gordon-Blake J; Lee H; Laham MS; Krider IS; Christie N; Ackerman-Berrier M; Penton C; Knowles NG; Musku SR; Fu J; Velma GR; Xiong R; Thatcher GRJ
    Biochemistry; 2023 Feb; 62(4):923-933. PubMed ID: 36746631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAMPT: A critical driver and therapeutic target for cancer.
    Gasparrini M; Audrito V
    Int J Biochem Cell Biol; 2022 Apr; 145():106189. PubMed ID: 35219878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
    Wang N; Pan D; Wang X; Su M; Wang X; Yan Q; Sun G; Wang S
    Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.